Akari Therapeutics PLC(AKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AKTX Akari Therapeutics PLC

交易中 05-18 13:35:19 EDT

3.55

+0.06

+1.72%

最高3.67	最低3.39	成交量7,086
今开3.39	昨收3.49	日振幅7.93%
总市值406.31万	流通市值306.46万	总股本114.45万
成交额2.49万	换手率0.82%	流通股本86.33万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AKTX","market":"US","secType":"STK","nameCN":"Akari Therapeutics PLC","latestPrice":3.55,"timestamp":1779125433762,"preClose":3.49,"halted":0,"volume":7086,"delay":0,"changeRate":0.017191977077363783,"floatShares":863273,"shares":1144533,"eps":-20.553658,"marketStatus":"交易中","change":0.06,"latestTime":"05-18 13:35:19 EDT","open":3.39,"high":3.6667,"low":3.39,"amount":24850.4517768,"amplitude":0.079284,"askPrice":3.69,"askSize":100,"bidPrice":3.13,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-20.553658,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":1,"adrRate":2000,"exchange":"NASDAQ","adjPreClose":3.49,"preHourTrading":{"tag":"盘前","latestPrice":3.29,"preClose":3.49,"latestTime":"09:16 EDT","volume":2644,"amount":9299.762352,"timestamp":1779110184696,"change":-0.2,"changeRate":-0.057307,"amplitude":0.13467},"postHourTrading":{"tag":"盘后","latestPrice":3.49,"preClose":3.49,"latestTime":"16:10 EDT","volume":2,"amount":6.98,"timestamp":1778875805030,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.222913},"requestUrl":"/m/hq/s/AKTX","defaultTab":"news","newsList":[{"id":"1149781574","title":"Akari Therapeutics PLC：Aktx-101进入IND支持性研究阶段，一期临床试验预计2026年末/2027年初启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1149781574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149781574?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:41","pubTimestamp":1777293688,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC宣布，其研发药物Aktx-101已正式进入IND支持性研究阶段。这一关键进展为后续的临床试验奠定了坚实基础。根据公司规划，该药物的一期临床试验预计将于2026年末至2027年初期间正式启动。\n此举标志着Akari Therapeutics在新药研发领域迈出重要一步。IND支持性研究的顺利推进，将为企业后续向监管机构提交新药临床试验申请提供必要数据支持。整个研发进程正按照既定时间表稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157451809","title":"Akari Therapeutics公布Aktx-101临床前积极数据 展示靶向RNA剪接的同类首创Trop2 ADC有效载荷差异化细胞毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1157451809","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157451809?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:38","pubTimestamp":1776688695,"startTime":"0","endTime":"0","summary":"Akari Therapeutics公司近日发布其创新药物Aktx-101的临床前研究数据，结果显示该靶向RNA剪接机制的首创型Trop2抗体偶联药物（ADC）有效载荷展现出显著差异化细胞毒性特征。实验数据表明，Aktx-101通过独特作用机制实现对癌细胞的精准杀伤，为ADC药物开发开辟了新方向。这项突破性进展凸显了该候选药物在治疗表达Trop2抗原的恶性肿瘤方面的潜在治疗价值，为后续临床研究奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104489368","title":"Akari Therapeutics参与虚拟投资者访谈，探讨与药明合联战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1104489368","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104489368?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:51","pubTimestamp":1775739103,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC日前参与了题为“这意味着什么”的虚拟投资者访谈活动，重点讨论了该公司与药明合联（WuXi XDC）达成的战略合作伙伴关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100548713","title":"Akari Therapeutics任命癌症生物学与RNA领域顶尖专家Prafulla Gokhale博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1100548713","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100548713?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:16","pubTimestamp":1772115409,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC（简称：Akari）宣布，任命在癌症生物学及RNA研究领域享有盛誉的专家Prafulla Gokhale博士加入其科学顾问委员会。Gokhale博士的加入将为公司在新药研发，尤其是肿瘤治疗方向的战略布局注入重要专业力量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157424138","title":"Akari Therapeutics任命RNA生物学与癌症研究领域全球知名专家Olga Anczukow博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1157424138","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157424138?lang=zh_cn&edition=full","pubTime":"2026-02-23 21:50","pubTimestamp":1771854616,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC（简称：Akari）近日宣布，任命在RNA生物学与癌症研究领域享有国际声誉的专家Olga Anczukow博士加入其科学顾问委员会。这一重要人事任命将进一步强化公司在相关科研领域的专业实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117866354","title":"Akari Therapeutics提交关键专利申请，并公布靶向CEACAM5表达实体瘤的第二款ADC项目Aktx-102","url":"https://stock-news.laohu8.com/highlight/detail?id=1117866354","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117866354?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:46","pubTimestamp":1769435176,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC已正式提交一项关键专利申请，并同时揭晓其第二款抗体偶联药物（ADC）项目——Aktx-102。该创新疗法旨在精准靶向表达CEACAM5的实体瘤，为相关癌症治疗开辟新的路径。\n此次专利布局与研发进展的公布，标志着公司在ADC领域迈出重要一步，有望进一步拓展其肿瘤治疗产品管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111534328","title":"药明合联启动AKTX-101 ADC项目的GMP生产以支持第一阶段首次人体临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1111534328","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111534328?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:31","pubTimestamp":1766496674,"startTime":"0","endTime":"0","summary":"药明合联启动AKTX-101 ADC项目的GMP生产，以支持第一阶段首次人体临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","BK4139","BK1141","BK4007","AKTX","LU2488822045.USD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119238470","title":"Akari Therapeutics宣布500万美元融资，包括同时进行的注册直接发行和按市场价格定价的私募","url":"https://stock-news.laohu8.com/highlight/detail?id=1119238470","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119238470?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:31","pubTimestamp":1765895470,"startTime":"0","endTime":"0","summary":"Akari Therapeutics宣布500万美元融资，包括同时进行的注册直接发行和按市场价格定价的私募。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517928921","title":"Akari Therapeutics Plc盘中异动 下午盘股价大跌5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517928921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517928921?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:26","pubTimestamp":1741199186,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时26分，Akari Therapeutics Plc股票出现波动，股价大幅跳水5.57%。截至发稿，该股报0.888美元/股，成交量1.9127万股，换手率0.07%，振幅5.85%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为1.34%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为950.74%、305.93%、302.08%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022627a2610822&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022627a2610822&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516320536","title":"Akari Therapeutics Plc股价拉升10.80% 市值涨16万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516320536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516320536?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:51","pubTimestamp":1741013472,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时51分，Akari Therapeutics Plc股票出现异动，股价大幅拉升10.80%。截至发稿，该股报0.964美元/股，成交量1.1219万股，换手率0.04%，振幅6.78%。Akari Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.02%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225112a25d45e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225112a25d45e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AKTX","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514389442","title":"Akari Therapeutics Plc股价拉升14.29% 市值涨53.49万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514389442?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:08","pubTimestamp":1740668891,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时08分，Akari Therapeutics Plc股票出现波动，股价急速上涨14.29%。截至发稿，该股报1.052美元/股，成交量105股，换手率0.00%，振幅0.00%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.80%。其相关个股中，Quoin Pharmaceuticals Ltd、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pds Biotechnology Corporation涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为633.35%、104.21%、101.93%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Biorestorative Therapies, Inc.，振幅分别为78.88%、35.71%、30.36%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272308119895181f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272308119895181f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856829","title":"Akari Therapeutics Plc股价飙升14.20% 市值涨390.64万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856829?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:37","pubTimestamp":1740580623,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时37分，Akari Therapeutics Plc股票出现异动，股价快速上涨14.20%。截至发稿，该股报1.039美元/股，成交量386股，换手率0.00%，振幅0.00%。Akari Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，Sab Biotherapeutics Inc C/Wts 22/10/2026 、Immunoprecise Antibodies Ltd.、Channel Therapeutics Corporation涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Immunoprecise Antibodies Ltd.较为活跃，换手率分别为135.54%、100.74%、80.35%，振幅较大的相关个股有Humacyte Inc C/Wts 27/08/2026 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Plus Therapeutics, Inc.，振幅分别为38.41%、27.33%、21.29%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223703abddee45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223703abddee45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","AKTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514301685","title":"Akari Therapeutics Plc盘中异动 快速下挫6.54%报0.935美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514301685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514301685?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:31","pubTimestamp":1740497477,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时31分，Akari Therapeutics Plc股票出现异动，股价快速下挫6.54%。截至发稿，该股报0.935美元/股，成交量4636股，换手率0.02%，振幅4.50%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.76%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1072.13%、964.25%、593.80%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、64.05%、61.16%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523311796300049&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523311796300049&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","AKTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513291168","title":"Akari Therapeutics Plc盘中异动 早盘大幅下挫7.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513291168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513291168?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:16","pubTimestamp":1740151010,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时16分，Akari Therapeutics Plc股票出现波动，股价急速跳水7.11%。截至发稿，该股报0.980美元/股，成交量5546股，换手率0.02%，振幅3.32%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为151.39%、100.24%、82.20%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为67.41%、57.50%、44.31%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221231650988de8fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221231650988de8fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512197862","title":"Akari Therapeutics Plc盘中异动 临近收盘大幅下跌5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512197862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512197862?lang=zh_cn&edition=full","pubTime":"2025-02-19 04:45","pubTimestamp":1739911544,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日04时45分，Akari Therapeutics Plc股票出现异动，股价快速下跌5.56%。截至发稿，该股报1.02美元/股，成交量7.324万股，换手率0.28%，振幅7.87%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.76%。其相关个股中，Aditxt, Inc.、Allogene Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为954.67%、220.28%、174.77%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219044544988a37c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219044544988a37c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511552590","title":"Akari Therapeutics Plc盘中异动 股价大跌5.04%报1.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511552590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511552590?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:31","pubTimestamp":1739457099,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时31分，Akari Therapeutics Plc股票出现波动，股价急速下挫5.04%。截至发稿，该股报1.13美元/股，成交量415股，换手率0.00%，振幅0.00%。Akari Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Genprex, Inc.较为活跃，换手率分别为977.79%、792.05%、90.75%，振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Omega Therapeutics, Inc.，振幅分别为30.00%、25.80%、9.38%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223139abcdb221&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223139abcdb221&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKTX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510208387","title":"Akari Therapeutics Plc盘中异动 急速上涨17.86%报1.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510208387","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510208387?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:31","pubTimestamp":1739284275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时31分，Akari Therapeutics Plc股票出现波动，股价快速拉升17.86%。截至发稿，该股报1.32美元/股，成交量516股，换手率0.00%，振幅0.89%。Akari Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.92%。其相关个股中，Dominari Holdings Inc.、In8Bio, Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.较为活跃，换手率分别为1854.98%、501.30%、169.12%，振幅较大的相关个股有In8Bio, Inc.、Dominari Holdings Inc.、Abpro Holdings, Inc，振幅分别为11.26%、8.28%、6.12%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112231159881bcbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112231159881bcbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","AKTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510639198","title":"Akari Therapeutics Plc盘中异动 股价大跌7.27%报1.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510639198","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510639198?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:43","pubTimestamp":1739198618,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时43分，Akari Therapeutics Plc股票出现异动，股价快速跳水7.27%。截至发稿，该股报1.15美元/股，成交量654股，换手率0.00%，振幅0.00%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.07%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022433898807aba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022433898807aba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKTX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509920922","title":"Akari Therapeutics Plc盘中异动 急速拉升5.63%报1.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509920922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509920922?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:24","pubTimestamp":1738859077,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时24分，Akari Therapeutics Plc股票出现异动，股价快速上涨5.63%。截至发稿，该股报1.20美元/股，成交量5545股，换手率0.02%，振幅6.12%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Lipella Pharmaceuticals Inc.、Equillium, Inc.、Transcode Therapeutics, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为5789.80%、1519.56%、153.03%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Equillium, Inc.，振幅分别为121.32%、53.02%、44.37%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002437987ca061&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002437987ca061&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKTX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509287992","title":"Akari Therapeutics Plc盘中异动 大幅拉升6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509287992","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509287992?lang=zh_cn&edition=full","pubTime":"2025-02-05 22:45","pubTimestamp":1738766706,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日22时45分，Akari Therapeutics Plc股票出现波动，股价快速上涨6.74%。截至发稿，该股报1.25美元/股，成交量535股，换手率0.00%，振幅2.14%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为1.60%。其相关个股中，Oragenics Inc.、Pasithea Therapeutics Corp.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Pasithea Therapeutics Corp.、Oragenics Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为3446.73%、962.70%、646.65%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Oragenics Inc.、Pasithea Therapeutics Corp.，振幅分别为54.05%、48.82%、37.50%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020522450796190b8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020522450796190b8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","AKTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akaritx.com","stockEarnings":[{"period":"1week","weight":-0.4416},{"period":"1month","weight":-0.243},{"period":"3month","weight":-0.6255},{"period":"6month","weight":-0.835},{"period":"1year","weight":-0.9339},{"period":"ytd","weight":-0.6981}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akari Therapeutics, Plc于2004年10月7日在英格兰和威尔士注册成立。该公司是一家临床阶段的生物技术公司，专注于开发涉及补体成分5（“C5”）和白三烯B4（“LTB4”）通路的自身免疫和炎症性疾病的先进疗法。这些途径中的每一种都在疾病靶向中具有科学上得到充分支持的致病作用。该公司认为，阻断炎症的早期介质将防止引发某些疾病的过程的启动和持续放大。公司自成立以来的活动包括进行研发活动和筹集资金。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.007289},{"month":2,"riseRate":0.25,"avgChangeRate":-0.164819},{"month":3,"riseRate":0.384615,"avgChangeRate":0.051328},{"month":4,"riseRate":0.461538,"avgChangeRate":0.052868},{"month":5,"riseRate":0.153846,"avgChangeRate":-0.169845},{"month":6,"riseRate":0.5,"avgChangeRate":0.049768},{"month":7,"riseRate":0.333333,"avgChangeRate":0.024132},{"month":8,"riseRate":0.5,"avgChangeRate":0.23135},{"month":9,"riseRate":0.5,"avgChangeRate":0.047326},{"month":10,"riseRate":0.25,"avgChangeRate":-0.130903},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.07207},{"month":12,"riseRate":0.25,"avgChangeRate":-0.096768}],"exchange":"NASDAQ","name":"Akari Therapeutics PLC","nameEN":"Akari Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akari Therapeutics PLC(AKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akari Therapeutics PLC(AKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akari Therapeutics PLC,AKTX,Akari Therapeutics PLC股票,Akari Therapeutics PLC股票老虎,Akari Therapeutics PLC股票老虎国际,Akari Therapeutics PLC行情,Akari Therapeutics PLC股票行情,Akari Therapeutics PLC股价,Akari Therapeutics PLC股市,Akari Therapeutics PLC股票价格,Akari Therapeutics PLC股票交易,Akari Therapeutics PLC股票购买,Akari Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akari Therapeutics PLC(AKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akari Therapeutics PLC(AKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}